Pivotal bioVenture Partners Investment Advisor LLC

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Pivotal bioVenture Partners Investment Advisor LLC reported 13 stock positions worth $307.8 million. Its top holding was Vaxcyte (PCVX) at 26.9% of the portfolio, followed by Arcutis Biotherapeutics (ARQT, 10.8%) and Trevi Therapeutics (TRVI, 10.6%). Compared with Q1 2026, it opened 1 new position, sold out of 1, added to 3 and reduced 4. The biggest buy was a new position in Avalyn Pharma (AVLN) and the biggest sale Oculis (OCS, shares −10%).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001844645
Portfolio Value
$307.8M (Q2 2026)
SEC Filing
0001012975-26-000759 ↗ filed Aug 13, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M Q1 2024: $155.6M Q1 2024 Q2 2024: $130.1M Q2 2024 Q3 2024: $168.5M Q3 2024 Q4 2024: $148.1M Q4 2024 Q1 2025: $123.6M Q1 2025 Q2 2025: $161.3M Q2 2025 Q3 2025: $173.0M Q3 2025 Q4 2025: $258.7M Q4 2025 Q1 2026: $279.8M Q1 2026 Q2 2026: $307.8M $307.8M Q2 2026

Holdings 13 stocks · $307.8M
PCVX Vaxcyte Inc. 26.92% 1,425,470 $82.9M Add +3.9%
ARQT Arcutis Biotherapeutics Inc. 10.78% 1,265,283 $33.2M Reduce -6.7%
TRVI Trevi Therapeutics Inc. 10.56% 1,742,672 $32.5M Add +12.2%
AVLN Avalyn Pharma Inc. 10.34% 966,792 $31.8M New
EVMN Evommune Inc. 8.32% 1,926,943 $25.6M No change
MPLT Maplight Therapeutics Inc. 7.12% 611,446 $21.9M Reduce 0.0%
OCS Oculis Holding AG 6.79% 1,506,250 $20.9M Reduce -10.4%
BIOA Bioage Labs Inc. 5.20% 653,374 $16.0M No change
IMNM Immunome Inc. 5.04% 732,512 $15.5M No change
ZBIO Zenas Biopharma Inc. 4.05% 490,766 $12.5M Reduce -17.1%
AVTX Avalo Therapeutics Inc. 2.61% 434,033 $8.0M Add +46.7%
RLYB Rallybio Corp. 1.56% 300,579 $4.8M No change
RXRX Recursion Pharmaceuticals-A 0.71% 595,518 $2.2M No change

Portfolio Sells Q1 2026 → Q2 2026
OCS Oculis Holding AG Reduce -10.4% 6.79% −9.18
ARQT Arcutis Biotherapeutics Inc. Reduce -6.7% 10.78% −0.64
ZBIO Zenas Biopharma Inc. Reduce -17.1% 4.05% −0.09
BOLT Bolt Biotherapeutics Inc. Sold out 0.00% −0.06
MPLT Maplight Therapeutics Inc. Reduce 0.0% 7.12% +2.68

Portfolio Buys Q1 2026 → Q2 2026
AVLN Avalyn Pharma Inc. New 10.34% +10.34
TRVI Trevi Therapeutics Inc. Add +12.2% 10.56% +3.93
AVTX Avalo Therapeutics Inc. Add +46.7% 2.61% +1.03
PCVX Vaxcyte Inc. Add +3.9% 26.92% −1.58

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 13$307.8MPCVX, ARQT, TRVI, AVLN, EVMN
Q1 2026 13$279.8MPCVX, OCS, EVMN, ARQT, TRVI
Q4 2025 12$258.7MPCVX, OCS, ARQT, EVMN, ZBIO
Q3 2025 10$173.0MPCVX, OCS, ARQT, ZBIO, TRVI
Q2 2025 12$161.3MOCS, PCVX, ARQT, INZY, ZBIO
Q1 2025 11$123.6MOCS, ARQT, PCVX, ZBIO, INZY
Q4 2024 11$148.1MPCVX, OCS, ARQT, INZY, ZBIO
Q3 2024 11$168.5MPCVX, INZY, ARQT, OCS, ZBIO
Q2 2024 10$130.1MPCVX, INZY, OCS, ARQT, EXAI
Q1 2024 11$155.6MPCVX, INZY, ARQT, OCS, FUSN